Prolactin and mental illness.
D000328:Adult; D000818:Animals; D001971:Bromocriptine / Q000627:therapeutic use; D004357:Drug Synergism; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D008094:Lithium / Q000494:pharmacology; D008297:Male; D001523:Mental Disorders / Q000097:blood*; D009638:Norepinephrine / Q000494:pharmacology; D009994:Osmolar Concentration; D011188:Potassium / Q000097:blood; D011293:Premenstrual Syndrome / Q000188:drug therapy; D011388:Prolactin / Q000009:adverse effects / Q000096:biosynthesis / Q000097:blood*; D011389:Prolactin Release-Inhibiting Factors / Q000378:metabolism; D051381:Rats; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents
D014662:Vasoconstrictor Agents; D001971:Bromocriptine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D011389:Prolactin Release-Inhibiting Factors; D008094:Lithium; D011188:Potassium; D009638:Norepinephrine